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OBJECTIVES: The incretin mimetic exenatide improves glycae-
mic control with associated weight reduction in patients with type
2 diabetes (T2DM) treated with metformin (MET) and/or a
sulphonylurea (SU), or MET and/or a thiazolidinedione. As a
drug’s pharmacokinetics and pharmacodynamics can vary with
age, we explored exenatide’s efﬁcacy and safety for patients <65 y
and 65 y in this post-hoc analysis. METHODS: Patients com-
pleting 3 y of exenatide treatment on background therapies of
MET and/or an SU (N = 217, age 58  10 y, 64% male, weight
99  18 kg, HbA1c 8.2  1.0%, fasting plasma glucose [FPG]
9.6  2.5 mmol/L, diabetes duration 8  6 y; mean  SD)
had statistically signiﬁcant (P < 0.05) mean (SE) changes in
HbA1c (-1.0  0.1%), FPG (-1.3  0.2 mmol/L), and weight
(-5.3  0.4 kg). The two subgroups (baseline age <65 y, N = 161,
53  7 y, and65 y, N = 56, 70  4 y) differed in baseline dura-
tion of diabetes (7  6 y, 11  6 y). RESULTS: The mean
(SE) changes in HbA1c (-0.9  0.1%, -1.2  0.2%), weight
(-5.2  0.5 kg, -5.4  0.6 kg), and FPG (-1.1  0.3 mmol/L,
-1.8  0.3 mmol/L) were not statistically different for the two
subgroups (all, P > 0.1). In patients completing 3.5 y of exenatide,
changes in lipids for the <65 y subgroup (N = 118) and 65 y
subgroup (N = 33) were not statistically different, as follows
(mmol/L): HDL cholesterol (+0.21  0.02, +0.25  0.03), LDL
cholesterol (-0.28  0.09, -0.37  0.15), total cholesterol
(-0.26  0.09, -0.33  0.16), and triglycerides (-0.49  0.17,
-0.52  0.14) (all, P > 0.2). Nausea and hypoglycaemia, themost
common adverse events, occurred at similar rates in both sub-
groups. The only case of severe hypoglycaemia occurred in a
patient <65 y whose background therapies were MET and an SU.
CONCLUSION: In summary, in this open-label extension study
of T2DM patients treated with MET and/or an SU, exenatide
exposure 3 y resulted in similar safety proﬁles and improve-
ments in glycaemic control and lipid concentrations, with associ-
ated weight reductions for patients 65 y and <65 y.
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OBJECTIVES: To compare the effectiveness of brand rosiglita-
zone maleate (BRM) versus generic rosiglitazone HCl (GRH) in
patients with type 2 diabetes mellitus, using computerized
records of a health care organization. METHODS: Comparison
of HbA1C reduction in patients starting treatment with either
BRM (n = 740) or GRH (n = 306) in the years 2004–2005.
RESULTS: BRM users were older (63.5  11 vs. 61.7  10 years
p < 0.001) and presented more cardiovascular disorders (38%
vs. 25%, p < 0.001) with no differences in gender distribution,
rates of hypertension or use of concomitant oral hypoglycemic
drugs. Use of concomitant insulin was more frequent (17.7% vs.
6.2%, p < 0.0001), rates of dispensed rosiglitazone doses
>4 mg/d (65.3% vs. 48.5%, p < 0.001) and treatment duration
was longer (9.3  6.2 vs. 5.2  2.2 months, p < 0.001) with the
generic formulation. Baseline HbA1C levels were higher
(9.0  1.5 vs. 8.6  1.2%, p < 0.001) and the absolute decrease
in HbA1C levels was greater in the GRH group (-1.2%  1.6%
vs. -0.5%  1.7%, p < 0.001). On multiple regression analysis,
the decrease in HbA1C (dependent variable) was associated
mainly with initial HbA1C level (partial r2 = 0.30). Rosiglita-
zone formulation (partial r2 = 0.02), age, treatment duration and
concomitant insulin (partial r2 = 0.006) were all signiﬁcant but
minor predictors, with no effect of rosiglitazone daily dose. Mean
regression-predicted decreases in HbA1C (with 95% CL) were
not signiﬁcantly different between the two rosiglitazone formu-
lations: -1.6% (-4.3% to +1.1%) for GRH and -1.1% (-3.8%
to +1.6%) for BRM. CONCLUSION: In this retrospective data-
base analysis, we found no evidence of different effectiveness of
generic vs. brand rosiglitazone in lowering HbA1C levels.
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OBJECTIVES: The objective of this study was to compare the
rate of micro- and macrovascular complications in type 2 diabe-
tes mellitus (T2DM) patients, from increased insulin use due to
the addition of inhaled human insulin Exubera (EXU) as a treat-
ment option versus subcutaneous (sc) insulin alone using the
Economic Assessment of Glycemic Control and Long-term
Effects(Eagle) model. METHODS: The model included uncon-
trolled T2DM patients eligible for insulin. Long-term conse-
quences were based on risk equations derived from DCCT,
UKPDS and WESDR. The model used Freemantle’s estimates for
year one. In the arm where EXU and sc insulin were available,
43% of patients initiated insulin therapy (35% inhaled and 8%
sc insulin) versus 16% when only sc insulin was available. The
subsequent yearly increase in insulin uptake was based on data
from the DIN-LINK study. The model assumed 8% of patients
remained on sc insulin. RESULTS: The mortality rate observed
after 10 years was 34.5% versus 36.3% with inhaled and sc
insulin versus sc insulin respectively. Complications observed
after 10 years, when inhaled and sc insulin were available vs. sc
insulin alone, were 14.7% vs. 16.1% for myocardial infarction
and stroke, 5.2% vs. 5.9% for proliferative retinopathy, 43.4%
vs. 47.3% for microalbuminuria and 14.1% vs. 17.2% for
clinical neuropathy. In sensitivity analyses, EXU’s advantages
remained when insulin uptake was capped at 60% (i.e. always at
least 40% on OADs). CONCLUSION: Delaying insulin initia-
tion increases the rate of complications. The results showed that
when insulin use is increased due to the availability of inhaled
insulin, a reduction in all-cause mortality and the number of
complications should be observed. Exubera has the potential to
improve diabetes management by overcoming barriers to insulin
initiation in T2DM patients, and could help prevent more long-
term complications associated with T2DM.
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EVALUATION OFTHE ASSOCIATION BETWEEN GLUCOSE
VARIABILITY,AS MEASURED BYTHE DIFFERENCE BETWEEN
MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD
GLUCOSE OBSERVATIONS,AND LONGTERM CLINICAL
OUTCOME IN SUBJECTS WITHTYPE 2 DIABETESTREATED
WITH INSULIN
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OBJECTIVES: The aim of this study was to determine if there
was an association between random blood glucose (RBG) obser-
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